We can’t show the full text here under this license.
Immune response, batch consistency, and long-term safety of the rVSVΔG-ZEBOV-GP vaccine in healthy adults
Updated
Abstract
Antibody responses to the Ebola vaccine increased by over 58-fold postvaccination and persisted through 24 months.
- Geometric mean titers of antibodies increased in all vaccine groups by 28 days and remained elevated for 24 months.
- All three manufacturing lots of the vaccine showed equivalent immunogenicity at 28 days.
- Neutralizing antibody levels peaked at 18 months with no decline observed through 24 months.
- At 28 days, at least 94% of vaccine recipients showed a significant , which remained above 91% at 24 months.
- Female sex and a history of arthritis may be associated with an increased risk of developing arthritis following vaccination.
Simplified
Key numbers
58×
Increase in Antibody Levels
Measured by ZEBOV-GP ELISA at 28 days post-vaccination.
94%
Rate
Percentage of participants achieving at 28 days post-vaccination.
2.2
Risk Factor Odds Ratio
Odds ratio for developing arthritis associated with female sex.